Université Paris-Saclay, UVSQ, ERPHAN, Versailles, France; AFM-Téléthon, Direction des Actions Médicales, Evry, France.
Service de Physiologie et explorations fonctionnelles, GHU APHP - Paris Saclay - Hôpital Raymond Poincaré (APHP), Garches, France; Université Paris-Saclay, UVSQ, INSERM U1179, Equipe 3 «END:ICAP», Versailles, France.
Arch Bronconeumol. 2023 Aug;59(8):488-496. doi: 10.1016/j.arbres.2023.05.002. Epub 2023 May 11.
Home noninvasive ventilation (NIV), targeting a reduction of carbon dioxide with a combination of sufficient inspiratory support and backup-rate improves outcomes in patients with chronic obstructive pulmonary disease. The aim of this systematic review with individual participant data (IPD) meta-analysis was to evaluate the effects of intensity of home NIV on respiratory outcomes in individuals with slowly progressive neuromuscular (NMD) or chest-wall disorders (CWD).
Controlled, non-controlled and cohort studies indexed between January-2000 and December-2020 were sought from Medline, Embase and the Cochrane Central Register. Outcomes were diurnal PaCO, PaO, daily NIV usage, and interface type (PROSPERO-CRD 42021245121). NIV intensity was defined according to the Z-score of the product of pressure support (or tidal volume) and backup-rate.
16 eligible studies were identified; we obtained IPD for 7 studies (176 participants: 113-NMD; 63-CWD). The reduction in PaCO was greater with higher baseline PaCO. NIV intensity per se was not associated with improved PaCO except in individuals with CWD and the most severe baseline hypercapnia. Similar results were found for PaO. Daily NIV usage was associated with improvement in gas exchange but not with NIV intensity. No association between NIV intensity and interface type was found.
Following home NIV initiation in NMD or CWD patients, no relationship was observed between NIV intensity and PaCO, except in individuals with the most severe CWD. The amount of daily NIV usage, rather than intensity, is key to improving hypoventilation in this population during the first few months after introduction of therapy.
家庭无创通气(NIV)通过结合足够的吸气支持和后备频率来降低二氧化碳,可改善慢性阻塞性肺疾病患者的预后。本项包含个体参与者数据(IPD)的系统评价和荟萃分析旨在评估家庭 NIV 的强度对进展缓慢的神经肌肉(NMD)或胸壁疾病(CWD)患者呼吸结局的影响。
从 Medline、Embase 和 Cochrane 中央注册库中检索了 2000 年 1 月至 2020 年 12 月期间发表的对照、非对照和队列研究。结果包括日间 PaCO2、PaO2、每日 NIV 使用情况和接口类型(PROSPERO-CRD 42021245121)。NIV 强度根据压力支持(或潮气量)和后备频率乘积的 Z 分数定义。
共确定了 16 项符合条件的研究;我们获得了其中 7 项研究的 IPD(176 名参与者:113 名 NMD;63 名 CWD)。基线 PaCO2 越高,PaCO2 的降低幅度越大。NIV 强度本身与 PaCO2 的改善无关,除了在 CWD 患者和基线高碳酸血症最严重的患者中。PaO2 也有类似的结果。每日 NIV 使用与气体交换的改善相关,但与 NIV 强度无关。未发现 NIV 强度与接口类型之间存在关联。
在 NMD 或 CWD 患者开始家庭 NIV 后,除了基线 CWD 最严重的患者外,NIV 强度与 PaCO2 之间未观察到相关性。在开始治疗后的头几个月内,每日 NIV 使用量而不是强度是改善该人群通气不足的关键。